Compare GRF & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | ALDX |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 39.2M |
| IPO Year | N/A | 2014 |
| Metric | GRF | ALDX |
|---|---|---|
| Price | $10.11 | $0.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 2.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.50 | $0.60 |
| 52 Week High | $11.85 | $5.93 |
| Indicator | GRF | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 30.34 |
| Support Level | $10.09 | N/A |
| Resistance Level | $10.55 | $1.58 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 74.33 | 15.60 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.